Document Actions

You are here: FRIAS Fellows Fellows 2016/17 Prof. Dr. A. Ganesan

Prof. Dr. A. Ganesan

University of East Anglia
Chemistry, organic and medicinal
External Senior Fellow (Marie S. Curie FCFP)
September 2016 - December 2017

Room 01 027
Phone +49 (0)761 203 97341
Fax +49 (0)761 203 97451


Ganesan graduated with a BSc (Hons) in Chemistry from the National University of Singapore and a PhD from the University of California-Berkeley supervised by Clayton H. Heathcock. After postdoctoral research with Gregory Verdine at Harvard University, he was a Senior Research Chemist at the Centre for Natural Product Research, Singapore (1993-96) and Principal Investigator at the Institute of Molecular and Cell Biology, Singapore (1996-99). In 1999 he joined the University of Southampton as a Reader in the Combinatorial Chemistry Centre for Excellence. In 2011 he became the Chair of Chemical Biology at the University of East Anglia’s School of Pharmacy. His research is focused on chemical biology, medicinal chemistry and organic synthesis. Ganesan is co-founder of the drug discovery company Karus Therapeutics, Chair of the EU COST Action CM1406 Epigenetic Chemical Biology and a member of the IUPAC Subcommittee for Medicinal Chemistry and Drug Development.

Selected Publications

  • Silva Júnior, P. E.; Rezende, L. C. D.; Gimenes, J. P.; Maltarollo, V. G.; Dale, J.; Trossini, G. H. G.; Emery, F. S.; Ganesan, A. Synthesis of Two ‘Heteroaromatic Rings of the Future’ for Applications in Medicinal Chemistry. RSC Adv. 2016, 6, 22777-22780.
  • Davidson, S. M.; Foote, K.; Kunuthur, S.; Gosain, R.; Tan, N.; Tyser, R.; Zhao, Y. J.; Graeff, R.; Ganesan, A.; Duchen, M. R.; Patel, S.; Yellon, D. M. Inhibition of NAADP Signalling on Reperfusion Protects the Heart by Preventing Lethal Calcium Oscillations via Two-Pore Channel 1 and Opening of the Mitochondrial Permeability Transition Pore. Cardiovasc. Res. 2015, 108, 357-366.
  • Hamon, M.; Dickinson, N.; Devineau, A.; Bolien, D.; Tranchant, M.-J.; Taillier, C.; Jabin, I.; Harrowven, D. C.; Whitby, R. J.; Ganesan, A.; Dalla, V. Intra- and Intermolecular Alkylation of N,O-Acetals and π-Activated Alcohols Catalyzed by in Situ Generated Acid. J. Org. Chem. 2014, 79, 1900-1912.
  • Tortorici, M.; Borrello, M. T.; Tardugno, M.; Chiarelli, L. R.; Pilotto, S.; Ciossani, G.; Vellore, N. A.; Bailey, S. G.; Cowan, J.; O’Connell, M.; Crabb, S. J.; Packham, G.; Mai, A.; Baron, R.; Ganesan, A.; Mattevi, A. Protein Recognition by Short Peptide Reversible Inhibitors of the Chromatin-Modifying LSD1/CoREST Lysine Demethylase. ACS Chem. Biol. 2013, 8, 1677-1682.
  • Benelkebir, H.; Donlevy, A. M.; Packham, G.; Ganesan, A. Total Synthesis and Stereochemical Assignment of Burkholdac B, a Depsipeptide HDAC Inhibitor. Org. Lett. 2011, 13, 6334-6337.

FRIAS Research Project

Targeting Histone-Modifying Enzymes for Epigenetic Drug Discovery

Epigenetics is the study of how DNA and histone protein modification affect gene transcription in eukaryotes. The DNA and protein modifications are carried out by writer enzymes. For each modification, an eraser enzyme returns the molecule to its native state.  In this project, we will target two key histone-modifying eraser enzymes, histone deacetylases (HDACs) and lysine-specific demethylase I (LSD1). HDAC inhibitors are a well validated epigenetic target for drug discovery with five approvals for cancer chemotherapy. However, there are issues with selectivity as the drugs inhibit several or all eleven of the human HDACs. Our approach is to design isoform-selective HDAC inhibitors and profile them biologically in order to understand the specificity that will be therapeutically valuable. In preliminary results, we have identified HDAC6 selective inhibitors. We will prepare two libraries of compounds based around two scaffolds and these will be evaluated in Freiburg. Concurrently, we will work on the second target, LSD1. We have a series of irreversible LSD1 inhibitors with submicromolar activity in acute myeloid leukaemia cell lines. We will prepare additional compounds in the series to optimize their pharmacodynamic and pharmacokinetic properties. In addition, we will identify scaffolds for reversible LSD1 inhibition through in silico screening. Promising candidates will be synthesized and tested in enzyme and cell-based assays for LSD1 inhibitory activity.